Total
0
Shares
Immutep (ASX:IMM) - CEO, Marc Voigt (left) - The Market Herald
CEO, Marc Voigt (left)
Source: ShareCafe
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotechnology company Immutep (IMM) has been advised by GSK that its phase two clinical trial on ulcerative colitis has been discontinued
  • IMM had been testing an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, on patients with the bowel disease
  • However, GSK has decided to stop the trial after conducting an assessment on the clinical data during a planned study break
  • The licencing partner now wants to assess the efficacy and safety data of GSK2831781, as well evaluate the biology to determine what happens next
  • Despite the trial being discontinued, Immutep's collaboration with GSK continues as does its three other trials for other treatments
  • Shares in IMM are trading down 8.14 per cent at 39.5 cents each

Biotechnology company Immutep (IMM) has been advised that its phase two clinical trial on ulcerative colitis has been discontinued.

Immutep teamed up with global healthcare company GSK to test an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, on patients with the bowel disease.

But, the trial has now been stopped by GSK on the basis that the business conducted an assessment on the clinical data during a planned study break.

The licencing partner said it needs to assess the efficacy and safety data of GSK2831781, as well as evaluate the biology to determine next steps for the program.

Despite the trial being discontinued, GSK's and Immutep's ongoing collaboration agreement remains in place for this treatment.

Under the terms of the deal, IMM is eligible to receive up to £54 million (around $95.5 million) in remaining milestone payments and additional royalties if GSK2831781 is commercialised.

Additionally, Immutep’s three other product candidates will continue being developed as planned — as the trial end has no financial impact on Immutep.

Following today's announcement though, the company's share price has dipped 8.14 per cent in the red at 39.5 cents each at 11:50 am AEDT.

IMM by the numbers
More From The Market Herald
Patrys (ASX:PAB) selects stable cell line for PAT-DX1 production

" AFT Pharmaceuticals (ASX:AFP) signs exclusive Maxigesic IV licensing agreement

AFT Pharmaceuticals has signed an exclusive Maxigesic IV licensing agreement for eight new European markets.
Althea Group (ASX:AGH) - CEO, Joshua Fegan - The Market Herald

" Althea Group’s (ASX:AGH) subsidiary gets A$137K order to make cannabis concentrates

Althea Group’s (AGH) subsidiary, Peak Processing Solutions, has received an C$134,000 (roughly A$137,216) purchase order from Peace Naturals Project.
Immutep (ASX:IMM) - CEO, Marc Voigt (left) - The Market Herald

" Immutep (ASX:IMM) expands TACTI-002 study

Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a recommendation from the data monitoring committee.
ImpediMed (ASX:IPD) - CEO, Rick Carreon - The Market Herald

" ImpediMed (ASX:IPD) completes 200,000 patient tests

ImpediMed  (IPD) says it has reached a milestone 200,000 patient tests for SOZO testing.